erlotinib hydrochloride has been researched along with quinine in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (quinine) | Trials (quinine) | Recent Studies (post-2010) (quinine) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 6,859 | 398 | 1,099 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | quinine (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 1 | Mus musculus (house mouse) | 0.28 | |
| Solute carrier family 22 member 2 | Mus musculus (house mouse) | 2.8 | |
| Potassium channel subfamily K member 2 | Homo sapiens (human) | 3.85 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 1.7 | |
| Cytochrome P450 2D26 | Rattus norvegicus (Norway rat) | 0.094 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.6285 | |
| Solute carrier family 22 member 1 | Rattus norvegicus (Norway rat) | 2.0333 | |
| Cytochrome P450 2D4 | Rattus norvegicus (Norway rat) | 1.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bergman, B; Branden, E; Gréen, H; Hornstra, N; Kentson, M; Koyi, H; Svedberg, A; Vikingsson, S; Vikström, A | 1 |
1 trial(s) available for erlotinib hydrochloride and quinine
| Article | Year |
|---|---|
Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3A; Drug Interactions; Drug Monitoring; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinine; Sex Factors | 2019 |